Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 6/20 | 0.44 |
| ▸ | MMP3 | P08254 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27975122 | 0.82 | MMP8 (0.47) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL7906077 | 0.81 | CA12 (0.45) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL3104630 | 0.80 | MMP8 (0.48) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL3098889 | 0.79 | NR1I3 (0.46) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL3102179 | 0.79 | NR1I3 (0.46) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL7909162 | 0.79 | MMP8 (0.43) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL3093406 | 0.78 | MMP8 (0.45) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL3090378 | 0.78 | MMP8 (0.45) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL3090372 | 0.78 | MMP8 (0.45) | MMP8MMP3NPC1RAB9ACA12 | |
| SCHEMBL19996133 | 0.78 | NPC1 (0.53) | NPC1RAB9ACA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN KETTERING INST CANCER (US) | 2015-10-01 | — | — | US | disclosed |
| US-9056857-B2 | Methods for treating or preventing cancer and neurodegenerative diseases | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2010075255-A2 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158017-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN2 | MMP8 2810/4885MMP3 1230/4885NPC1 86/4885 |
| US-20150272962-A1 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN2 | MMP8 2810/4885MMP3 1230/4885NPC1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.